NIB and Nokia agree EUR 250 million financing for 5G research and development
Press release NIB loan will be used on 5G technology research and development in Europe 3 December 2018 Espoo, Finland […]
MGX Minerals Reports High Grade Gold Mineralization at Depth at Fran Gold Project, British Columbia; Drilling to Re-Commence
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: […]
NIO Inc. Provides November 2018 Monthly Delivery and Production Update, Announces NIO Day, December 15, 2018, as ES6 Launch Date
Delivered 3,089 ES8 vehicles in November 2018 Cumulative Production of ES8 exceeded 10,000 Milestone Announces NIO Day, December 15, 2018, […]
Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications
Novel small molecule FF-10158 targets integrin alphavbeta3 (avβ3) and alphavbeta5 (avβ5) receptors Expands theragnostic pipeline Potential broad application in the […]
Total voting rights
Total Voting Rights December 3, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with 5.6.1R of […]
Mkango Intersects Highest Grade Rare Earths Mineralisation to Date in Final Drill Results From the Songwe Hill Project in Malawi and Commences Resource Update
LONDON and VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — Mkango Resources Ltd. (AIM / TSXV: MKA) (the “Company” […]
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a […]
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia
Detailed Phase 2 ITP data show clear correlation between IgG reduction, platelet count increase and reduction of bleeding events ITP […]
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
Regulated information – Inside information Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies in deal totaling up […]
